'Harmless' microbe may cause death of good gut bacteria

Medicalnewstoday | April 15, 2019

Good bacteria are imperative for gut health. New research finds that another type of gut microbe could be endangering the beneficial bacteria population. Trillions of microbes are present in the gut. The majority are bacteria. However, other types — including viruses and single cell eukaryotes (SCE) — exist. Few studies have examined SCEs, as many believe they are innocuous. However, new research led by the Yong Loo Lin School of Medicine (NUS Medicine) in Singapore has found that one common SCE — Blastocystis — could be destroying "good" forms of bacteria. According to the Centers for Disease Control and Prevention (CDC), Blastocystis is transmittable via consuming contaminated food or water or having exposure to infected animals. Some people believe it may be responsible for intestinal infection, but it is possible to stay healthy even with the microbe's presence. One subtype of Blastocystis called ST7 seems to be distinct from the rest. Instead of remaining harmless, it endangers other bacteria.

Spotlight

This document describes a novel Quanterix lysate diluent for running lysate samples with Simoa assays diluent.

Spotlight

This document describes a novel Quanterix lysate diluent for running lysate samples with Simoa assays diluent.

Related News

MEDICAL

Targeting Chronic Infections in Cystic Fibrosis, Cystic Fibrosis Foundation Invested in Felix Biotechnology

Felix Biotechnology | March 07, 2022

Felix Biotechnology, a biopharmaceutical business focusing on developing first-in-class, long-lasting antibacterial medicines to treat chronic drug-resistant infections, announced that it has received a Therapeutics Development Award from the Cystic Fibrosis Foundation. The funding will aid Felix's efforts to develop a novel medication to treat chronic Pseudomonas aeruginosa lung infections. Chronic P. aeruginosa infections affect half of the persons with cystic fibrosis, many of whom are multidrug-resistant. Since infections are the leading cause of death in cystic fibrosis patients, innovative treatments are urgently needed. Felix offers a novel strategy by turning bacteria's natural predators, microscopic viruses known as bacteriophage (or phage), into long-lasting, broadly effective medicines. Felix's phage therapies are specifically designed to examine and drive positive evolutionary effects of phage treatment, based on foundational research by Yale University's Drs. Paul Turner, Ben Chan, and Jon Koff. This results in a more long-lasting treatment, which is essential given the requirement to regularly deliver phage to treat chronic infections. This medication is now being tested in a clinical trial at Yale University. More information about the experiment can be found here, and interested patients are encouraged to enroll if they are eligible. We are incredibly honored and excited to receive this support from the CF Foundation, This award will speed Felix in its mission to provide new therapeutic options to patients dealing with life-threatening infections and to develop phage as a broadly applicable antibacterial therapy." Dr. Paul Turner, Ph.D., co-founder of Felix.

Read More

Pressure BioSciences Announces the Achievement of a Critical Milestone in Revolutionary Nanoemulsification Technology Development

Pressure BioSciences, Inc. | October 07, 2020

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("UST™")-based nanoemulsification system. Following achievement of this milestone, the Company has begun to build the initial "Alpha" unit of the commercial model. Once built, tested, and approved, the Company will immediately proceed to build an additional 15 ready-for-sale systems, thus enabling PBI to meet its goal of shipping the BaroShear K45 UST System in early (Q1/Q2) 2021. Based on the Company's patented UST platform, the BaroShear K45 is a unique breakthrough nanoemulsification system designed to resolve one of the most substantive problems facing manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products), and other products containing oil-based active ingredients that are at best poorly soluble in water. As with any oil-based product, it is difficult for the water-based biochemistry of humans and other animals to access and absorb the active ingredients hidden within oil drops. Poor water solubility leads to lower absorption and bioavailability of active ingredients, which makes it particularly difficult to design and deliver proper dosing of the desired compound. More recently, growing science around nanoemulsion development has shown that oil-based active ingredients manufactured into high quality nanoemulsions have delivered dramatically increased absorption and bioavailability, resulting in higher quality finished products for the consumer.

Read More

CELL AND GENE THERAPY

Terumo Blood and Cell Technologies to Collaborate with CSL Plasma on U.S. FDA Clearance of Plasma Collection Technology

CSL Plasma | March 11, 2022

CSL Plasma, a division of global biotherapeutics pioneer CSL Behring, announced the Rika Plasma Donation System created by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado, has received regulatory approval. The new plasmapheresis system is expected to provide technologies to support a safe, efficient, and better experience for plasma donors and an improved experience for CSL Plasma personnel, according to Terumo Blood and Cell Technologies. Additional characteristics of the new Rika system, according to CSL Plasma, will allow for the collection of more plasma in less time, hence improving quality and safety and, in turn, better serving patients who rely on plasma-based therapies. These advantages include: On average, Rika completes one plasma collection in 35 minutes or less: Compared to previous average CSL Plasma donation timings, this might mean a nearly 30% reduction in donor donation time. It assures that no more than 200 milliliters of blood are ever removed from the donor's body. This is believed to make the donor more comfortable during the donation process and lessen the risk of red cell loss deferral. It has a sophisticated user interface that helps CSL Plasma front-line personnel operate the equipment. This milestone helps bring to life how we demonstrate innovation, collaboration, and patient-focus, part of the CSL Values that underpin our commitment to manufacturing and delivering life-saving and life-extending medicines around the world, We continue to evolve as a leading biotechnology company, investing in our core plasma business. Continued innovation that benefits our employees and plasma donors speak to how we are driven by our promise to save and improve lives around the world." CSL Chief Operating Officer Paul McKenzie. CSL Plasma will begin installing the new technology at locations in the Denver, Colorado, area in the following months. There is a critical and ongoing need for human plasma to produce life-saving medicines for people with serious and rare diseases, CSL Plasma's decision to work with Terumo Blood and Cell Technologies is consistent with our business goals to improve the donor and employee experience through innovation and remain the plasma donation center of choice. We look forward to rolling out this new technology." CSL Plasma General Manager Michelle Meyer.

Read More